文献速递中毒与环境急症儿科与产科急症

儿童意外美沙酮与丁丙诺啡中毒:配对观察研究

Unintentional buprenorphine and methadone poisoning in children: a matched observational study.
PubMed 文献 · Clin Toxicol (Phila) · 2021-01-21
一句话结论儿童美沙酮中毒比丁丙诺啡中毒更严重:呼吸暂停仅见于美沙酮组,且需更大剂量纳洛酮。

该配对观察研究纳入≤12岁儿童,比较美沙酮(90例)与丁丙诺啡(30例)急性中毒的临床指标与院内并发症。美沙酮组呼吸暂停率显著更高(20/90 vs 0/30,OR=17.7,95%CI 1.1–302.8,p=0.047),初始纳洛酮推注中位剂量(0.4 vs 0.02 mg,p=0.014)和维持输注中位剂量(14.4 vs 2.4 mg,p<0.001)均更高;丁丙诺啡组入院时意识丧失比例更高但后续并发症更少。提示儿童美沙酮暴露毒性高于丁丙诺啡。

要点

  • 儿童美沙酮中毒出现呼吸暂停20/90例,丁丙诺啡组0/30例(OR=17.7,95%CI 1.1–302.8,p=0.047)。
  • 美沙酮组初始纳洛酮推注中位剂量0.4 mg,丁丙诺啡组0.02 mg(p=0.014)。
  • 美沙酮组纳洛酮维持输注中位剂量14.4 mg,丁丙诺啡组2.4 mg(p<0.001)。
  • 仅5例美沙酮中毒需气管插管(5.5%),全部患儿存活。

适用人群与场景

  • ≤12岁儿童,因急性美沙酮或丁丙诺啡中毒于2018年3月至2019年3月入住研究中心。
  • 美沙酮组90例,丁丙诺啡组30例,均为意外中毒病例。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 美沙酮中毒儿童需更高剂量纳洛酮:初始推注中位0.4 mg,维持输注中位14.4 mg(原文未提及具体给药途径、频次和目标值)。
  • 丁丙诺啡中毒儿童纳洛酮初始推注中位0.02 mg,维持输注中位2.4 mg(原文未提及具体给药途径、频次和目标值)。
  • 仅5例美沙酮中毒需气管插管(5.5%),全部患儿存活。

红旗征与不能漏的情况

  • 呼吸暂停(原文定义为呼吸暂停/呼吸过缓主要结局的一部分):美沙酮组20/90例出现呼吸暂停,丁丙诺啡组0/30例。
  • 意识丧失:丁丙诺啡组入院时意识丧失比例更高,但后续并发症更少。

研究设计与关键结果

  • 配对观察研究,单中心,纳入≤12岁儿童,美沙酮组90例、丁丙诺啡组30例。
  • 主要终点呼吸暂停/呼吸过缓:呼吸暂停美沙酮20/90 vs 丁丙诺啡0/30(OR=17.7,95%CI 1.1–302.8,p=0.047);呼吸过缓39/90 vs 10/30(p=ns)。
  • 次要终点:初始纳洛酮推注中位剂量0.4 vs 0.02 mg(p=0.014);维持输注中位剂量14.4 vs 2.4 mg(p<0.001);瞳孔缩小与呼吸过缓相关(OR=3.2,95%CI 1.1–9.3,p=0.026);插管5例(5.5%)均为美沙酮组(p=ns);全部存活。

证据类型、等级与局限

  • 研究类型:配对观察研究,单中心。
  • 局限:样本量小(美沙酮90例、丁丙诺啡30例),单中心,观察性设计,可能存在混杂。

对床旁实践的改变

  • 儿童疑似阿片类中毒时,美沙酮暴露需警惕更高呼吸暂停风险和更高纳洛酮需求。
  • 丁丙诺啡中毒儿童入院时意识丧失更常见,但后续并发症较少,可能与其部分拮抗效应有关。
  • 瞳孔缩小伴呼吸过缓提示阿片类中毒,需及时评估呼吸状态。
  • 原文未提及具体纳洛酮给药途径、频次和目标值,临床使用时需结合实际情况。

指南或共识出处

  • Clin Toxicol (Phila) 发表的原始研究:Unintentional buprenorphine and methadone poisoning in children: a matched observational study.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare accidental pediatric poisoning from methadone vs. buprenorphine in terms of clinical indicators and in-hospital morbidity.

METHODS: A matched observational study conducted on children aged ≤12 years admitted to our center between March 2018 and March 2019 with acute poisoning from methadone or buprenorphine. Data were extracted from the electronic patient files of the pediatric methadone poisoning cases, and buprenorphine poisoning cases were followed from ED, during the study period. Cases were compared regarding rates of bradypnea/apnea (primary outcome), the need for antidote therapy and intubation, duration of hospital stay, miosis, loss of consciousness, blood gas analyses, and mortality (secondary outcomes).

RESULTS: A total of 90 methadone- and 30 buprenorphine-poisoned children were evaluated. Methadone cases had significantly higher rates of apnea (20/90 methadone vs. 0/30 buprenorphine; OR = 17.7, 95% CI 1.1, 302.8; p = 0.047), but there was no group difference in bradypnea (39/90 methadone vs. 10/30 buprenorphine; p = ns). 28 (31%) methadone and 3 buprenorphine (10%) cases had been referred to as fully awake (p = 0.013). Methadone cases required higher median naloxone doses for initial bolus (0.4 vs. 0.02 mg; p = 0.014) and maintenance infusion (14.4 vs. 2.4 mg; p < 0.001). 20 apnea cases (all from the methadone group) had miotic pupils, and miotic pupils were seen in 44 (90%) cases with bradypnea (OR = 3.2, 95% CI 1.1, 9.3; p = 0.026). Intubation was needed in only 5 methadone cases (5.5%; p = ns). All patients survived.

CONCLUSION: Compared to children poisoned with methadone, buprenorphine cases had higher rates of loss of consciousness on admission but subsequently experienced fewer complications during hospital treatment, which is likely due to the buprenorphine partial antagonist effect. Our findings suggest that methadone exposure is more toxic than buprenorphine in pediatric populations.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Farnaghi F, Gholami N, Hassanian-Moghaddam H, et al. Unintentional buprenorphine and methadone poisoning in children: a matched observational study. Clin Toxicol (Phila). 2021. PMID: 33475438. doi:10.1080/15563650.2020.1869755

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。